Cochlear (ASX:COH) share price edges higher to break 52-week record

It's been a great year so far for the hearing solutions company.

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price has delivered a stellar performance so far in 2021.

Since the start of the year, the hearing solution company's shares have continued on their upwards trajectory, gaining almost 30%.

However, today Cochlear shares reached an important milestone, breaking a new 52-week high of $244.62.

With no news released to the ASX today, let's take a look at Cochlear's most recent price-sensitive announcement.

What's been pushing the Cochlear share price higher?

Investors have been buying up Cochlear shares over the last 6 months following the company's positive February half-year results.

For the 6-month period, Cochlear reported sales revenue of $742.8 million, down 4% against the first half of FY20's result. While this may appear disappointing, when looking closer, surgeries recovered towards the second quarter following the easing of COVID-19 shutdowns.

Sales revenue dropped 8% in the first quarter, but rebounded to edge 8% higher in the following 3 months (Q2 FY21). Cochlear attributed the performance to varying degrees of growth across established versus emerging international markets. The United States, Japan, South Korea, and China recorded robust sales, while India and Brazil struggled with volumes.

On the bottom line, the company posted an underlying net profit of $125.3 million, falling 6% against a COVID-free first-half period (H1 FY20). The result was driven by a solid recovery in sales revenue and lower operating expenses due to material COVID-related savings.

Cochlear is projecting it will achieve FY21 underlying net profit between $225 million and $245 million. This is a 46% to 59% increase on last year's FY20 result.

The company noted that the deployment of COVID-19 vaccines, and rapid return of surgeries, is a positive sign for its resilient business.

Broker update

After reporting its first-half results, a number of brokers rated the company with varying price points. Investment firm, Macquarie raised its price target for Cochlear by 1.7% to $245.00. Morgan Stanley followed suit to also increase its rating by 6.1% to $227.00. The most recent broker note came from Credit Suisse in late May, which initiated a price of $225.00 for the hearing solutions company.

At today's market close, the Cochlear share price had slightly retreated from its 52-week high to $243.46, up 0.58% for the day.

Should you invest $1,000 in Woolworths Group Limited right now?

Before you buy Woolworths Group Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Woolworths Group Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »